Go Back
Egle
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio PhD, Director of the Translational Immunotherapy Team at Institut Curie, Egle Therapeutics is developing first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
More Details
Our Science
Egle’s scientific foundations benefits from decades of breakthrough academic research leading to unprecedented computational based IL-2 modified variants and a unique translational-based target discovery platform unveiling novel therapeutic Treg targets.
The key element of Egle’s core approach leverages of unifying therapeutic potentials of antibody specific targeting combined with the selective mechanism of action of modified cytokine for arming or disarming the most immunosuppressive Tregs to restore the immune response.
Egle deploys its first-in-class technology platforms to building a furnished drug pipeline of novel immunotherapies against Tregs with tremendous potential in the oncology and auto-immunity fields.
